Akèy › Limfòm selil B › Oregon
Etid klinik pou Limfòm selil B nan Oregon
5 etid pou Limfòm selil B ap chèche patisipan nan sit nan Oregon.
Vil nan Oregon
Tèks ofisyèl etid la (Anglè)
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Portland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06564038Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Oncology Associates of Oregon, Eugene
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07520006DALY II USA/ MB-CART2019.1 for DLBCL
- Oregon Health and Science University Knight Cancer Institute, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Oregon Health & Science University, Portland
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.